MicroRNA-33b-5p is overexpressed and inhibits GLUT4 by targeting HMGA2 in polycystic ovarian syndrome: An in vivo and in vitro study

Yang,Ying; Jiang,Hua; Xiao,Ling; Yang,Xuezhou

doi:10.3892/or.2018.6375

MicroRNA-33b-5p is overexpressed and inhibits GLUT4 by targeting HMGA2 in polycystic ovarian syndrome: An in vivo and in vitro study

Authors:
- Ying Yang
- Hua Jiang
- Ling Xiao
- Xuezhou Yang
View Affiliations

Affiliations: Department of Endocrinology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441021, P.R. China, Department of Clinical Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441021, P.R. China, Department of Gynecology, Xiangyang Maternal and Child Health Care Hospital, Xiangyang, Hubei 441021, P.R. China, Center for Reproductive Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441021, P.R. China
Published online on: April 18, 2018 https://doi.org/10.3892/or.2018.6375
Pages: 3073-3085

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disease, but its pathogenesis remains largely unknown. The present study explored the role of microRNA‑33b‑5p (miR‑33b‑5p) in PCOS pathogenesis, with a particular focus on its role in regulating glucose transporter 4 (GLUT4). A rat model of PCOS was developed by injecting female SD rats with insulin and HCG. miR‑33b‑5p, GLUT4, sterol regulatory element‑binding protein 1 (SREBF1), and high mobility group A2 (HMGA2) expression in rat ovarian tissues was examined by qRT‑PCR and immunohistochemistry. The effect of a high dose of either glucose or insulin on miR‑33b‑5p, GLUT4, SREBF1 and HMGA2 expression was also examined in cultured adipocytes by qRT‑PCR and western blotting. Additionally, the luciferase reporter assay and chromatin immunoprecipitation (ChIP) were used to explore the role of miR‑33b‑5p in regulating HMGA2, SREBF‑1 and/or GLUT4. Elevated levels of miR‑33b‑5p expression were detected in the ovarian tissues of insulin resistant PCOS rats, and those levels were negatively correlated with those of GLUT4, HMGA2 and SREBF1 expression (P<0.05). Immunohistochemistry studies revealed that GLUT4, SREBF1, and HMGA2 expression levels in the ovarian tissues of insulin resistant PCOS rats were significantly lower than those in other groups of rats. In cultured adipocytes, excess extracellular glucose or insulin increased miR‑33b‑5p expression but reduced GLUT4, SREBF1 and HMGA2 expression, whereas the levels of GLUT4, SREBF1 and HMGA2 were elevated by inhibition of miR‑33b‑5. HMGA2 could directly bind to the 5'‑promoter region of GLUT4 and promote its expression, and could also promote SREBF1 expression. Moreover, SREBF1 could also directly bind to the 5'‑promoter region of GLUT4 and promote its expression. Our findings revealed that miR‑33b‑5p was overexpressed in the ovarian tissues of insulin resistant PCOS rats, and thus may play an important role in the development of insulin resistance in PCOS patients. miR‑33b‑5p can inhibit GLUT4 production by targeting HMGA2, and in addition, HMGA2 and SREBF1 are important molecules involved in modulating GLUT4 expression.

View Figures

View References

1	Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ and Yildiz BO: Polycystic ovary syndrome. Nat Rev Dis Primers. 2:160572016. View Article : Google Scholar : PubMed/NCBI
2	Barber TM, Dimitriadis GK, Andreou A and Franks S: Polycystic ovary syndrome: Insight into pathogenesis and a common association with insulin resistance. Clin Med. 16:262–266. 2016. View Article : Google Scholar
3	Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM and Andersen Nyboe A: The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 29:791–801. 2014. View Article : Google Scholar : PubMed/NCBI
4	Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, Wei Z, Song X, Wang X, Fu S, et al: Prevalence of polycystic ovary syndrome in women in China: A large community-based study. Hum Reprod. 28:2562–2569. 2013. View Article : Google Scholar : PubMed/NCBI
5	Marciniak A, Rutkowska Nawrocka J, Brodowska A, Wiśniewska B and Starczewski A: Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Ann Agric Environ Med. 23:537–541. 2016. View Article : Google Scholar : PubMed/NCBI
6	Merz CNB, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-DeHoff RM, Johnson BD, et al: Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Womens Health. 25:875–881. 2016. View Article : Google Scholar
7	Velija-Asimi Z, Burekovic A, Dujic T, Dizdarevic-Bostandzic A and Semiz S: Incidence of prediabetes and risk of developing cardiovascular disease in women with polycystic ovary syndrome. Bosn J Basic Med Sci. 16:298–306. 2016.PubMed/NCBI
8	Jeanes YM and Reeves S: Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: Diagnostic and methodological challenges. Nutr Res Rev. 30:97–105. 2017. View Article : Google Scholar : PubMed/NCBI
9	Morgan BJ, Chai SY and Albiston AL: GLUT4 associated proteins as therapeutic targets for diabetes. Recent Pat Endocr Metab Immune Drug Discov. 5:25–32. 2011. View Article : Google Scholar : PubMed/NCBI
10	Govers R: Cellular regulation of glucose uptake by glucose transporter GLUT4. Adv Clin Chem. 66:173–240. 2014. View Article : Google Scholar : PubMed/NCBI
11	Johansson J, Feng Y, Shao R, Lönn M, Billig H and Stener-Victorin E: Intense electroacupuncture normalizes insulin sensitivity, increases muscle GLUT4 content, and improves lipid profile in a rat model of polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 299:E551–E559. 2010. View Article : Google Scholar : PubMed/NCBI
12	Mozzanega B, Mioni R, Granzotto M, Chiarelli S, Xamin N, Zuliani L, Sicolo N, Marchesoni D and Vettor R: Obesity reduces the expression of GLUT4 in the endometrium of normoinsulinemic women affected by the polycystic ovary syndrome. Ann NY Acad Sci. 1034:364–374. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhai J, Liu CX, Tian ZR, Jiang QH and Sun YP: Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. Biol Reprod. 87:292012. View Article : Google Scholar : PubMed/NCBI
14	Xi Y, Shen W, Ma L, Zhao M, Zheng J, Bu S, Hino S and Nakao M: HMGA2 promotes adipogenesis by activating C/EBPβ-mediated expression of PPARγ. Biochem Biophys Res Commun. 472:617–623. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yuan Y, Xi Y, Chen J, Zhu P, Kang J, Zou Z, Wang F and Bu S: STAT3 stimulates adipogenic stem cell proliferation and cooperates with HMGA2 during the early stage of differentiation to promote adipogenesis. Biochem Biophys Res Commun. 482:1360–1366. 2017. View Article : Google Scholar : PubMed/NCBI
16	Oishi Y, Spann NJ, Link VM, Muse ED, Strid T, Edillor C, Kolar MJ, Matsuzaka T, Hayakawa S, Tao J, et al: SREBP1 contributes to resolution of pro-inflammatory TLR4 signaling by reprogramming fatty acid metabolism. Cell Metab. 25:412–427. 2017. View Article : Google Scholar : PubMed/NCBI
17	Shafiee MN, Mongan N, Seedhouse C, Chapman C, Deen S, Abu J and Atiomo W: Sterol regulatory element binding protein-1 (SREBP1) gene expression is similarly increased in polycystic ovary syndrome and endometrial cancer. Acta Obstet Gynecol Scand. 96:556–562. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yang L, Chen J, Li Y, Wang Y, Liang S, Shi Y, Shi S and Xu Y: Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics. World J Biol Psychiatry. 17:467–474. 2016. View Article : Google Scholar : PubMed/NCBI
19	Flowers E, Froelicher ES and Aouizerat BE: MicroRNA regulation of lipid metabolism. Metabolism. 62:12–20. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ebert MS and Sharp PA: Roles for microRNAs in conferring robustness to biological processes. Cell. 149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
21	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yates LA, Norbury CJ and Gilbert RJC: The long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
23	Osmai M, Osmai Y, Bang-Berthelsen CH, Pallesen EM, Vestergaard AL, Novotny GW, Pociot F and Mandrup-Poulsen T: MicroRNAs as regulators of beta-cell function and dysfunction. Diabetes Metab Res Rev. 32:334–349. 2016. View Article : Google Scholar : PubMed/NCBI
24	Vienberg S, Geiger J, Madsen S and Dalgaard LT: MicroRNAs in metabolism. Acta Physiol. 219:346–361. 2017. View Article : Google Scholar
25	Cruz KJ, de Oliveira AR, Morais JB, Severo JS and Marreiro DD: Role of microRNAs on adipogenesis, chronic low-grade inflammation, and insulin resistance in obesity. Nutrition. 35:28–35. 2017. View Article : Google Scholar : PubMed/NCBI
26	Williams MD and Mitchell GM: MicroRNAs in insulin resistance and obesity. Exp Diabetes Res. 2012:4846962012. View Article : Google Scholar : PubMed/NCBI
27	Chen YH, Heneidi S, Lee JM, Layman LC, Stepp DW, Gamboa GM, Chen BS, Chazenbalk G and Azziz R: miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes. 62:2278–2286. 2013. View Article : Google Scholar : PubMed/NCBI
28	Hossain MM, Cao M, Wang Q, Kim JY, Schellander K, Tesfaye D and Tsang BK: Altered expression of miRNAs in a dihydrotestosterone-induced rat PCOS model. J Ovarian Res. 6:362013. View Article : Google Scholar : PubMed/NCBI
29	Ilie IR and Georgescu CE: Polycystic ovary syndrome-epigenetic mechanisms and aberrant microRNA. Adv Clin Chem. 71:25–45. 2015. View Article : Google Scholar : PubMed/NCBI
30	Jiang L, Huang J, Li L, Chen Y, Chen X, Zhao X and Yang D: MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome. J Clin Endocrinol Metab. 100:E729–E738. 2015. View Article : Google Scholar : PubMed/NCBI
31	Sørensen AE, Udesen PB, Wissing ML, Englund AL and Dalgaard LT: MicroRNAs related to androgen metabolism and polycystic ovary syndrome. Chem Biol Interact. 259:8–16. 2016. View Article : Google Scholar : PubMed/NCBI
32	Yin M, Wang X, Yao G, Lü M, Liang M, Sun Y and Sun F: Transactivation of microRNA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins. J Biol Chem. 289:18239–18257. 2014. View Article : Google Scholar : PubMed/NCBI
33	Poretsky L, Clemons J and Bogovich K: Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism. 41:903–910. 1992. View Article : Google Scholar : PubMed/NCBI
34	Adams BD, Parsons C, Walker L, Zhang WC and Slack FJ: Targeting noncoding RNAs in disease. J Clin Invest. 127:761–771. 2017. View Article : Google Scholar : PubMed/NCBI
35	Yee D, Coles MC and Lagos D: microRnAs in the lymphatic endothelium: Master regulators of lineage plasticity and inflammation. Front Immunol. 8:1042017. View Article : Google Scholar : PubMed/NCBI
36	Butz H, Kinga N, Racz K and Patocs A: Circulating miRNAs as biomarkers for endocrine disorders. J Endocrinol Invest. 39:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
37	Derghal A, Djelloul M, Trouslard J and Mounien L: An emerging role of micro-RNA in the effect of the endocrine disruptors. Front Neurosci. 10:3182016. View Article : Google Scholar : PubMed/NCBI
38	Jiang L, Huang J, Chen Y, Yang Y, Li R, Li Y, Chen X and Yang D: Identification of several circulating microRNAs from a genome-wide circulating microRNA expression profile as potential biomarkers for impaired glucose metabolism in polycystic ovarian syndrome. Endocrine. 53:280–290. 2016. View Article : Google Scholar : PubMed/NCBI
39	Li C, Chen L, Zhao Y, Chen S, Fu L, Jiang Y, Gao S, Liu Z, Wang F, Zhu X, et al: Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model. Gene. 598:20–26. 2017. View Article : Google Scholar : PubMed/NCBI
40	Salimi-Asl M, Mozdarani H and Kadivar M: Up-regulation of miR-21 and 146a expression and increased DNA damage frequency in a mouse model of polycystic ovary syndrome (PCOS). Bioimpacts. 6:85–91. 2016. View Article : Google Scholar : PubMed/NCBI
41	Sørensen AE, Wissing ML, Englund ALM and Dalgaard LT: MicroRNA species in follicular fluid associating with polycystic ovary syndrome and related intermediary phenotypes. J Clin Endocrinol Metab. 101:1579–1589. 2016. View Article : Google Scholar : PubMed/NCBI
42	Zhang CL, Wang H, Yan CY, Gao XF and Ling XJ: Deregulation of RUNX2 by miR-320a deficiency impairs steroidogenesis in cumulus granulosa cells from polycystic ovary syndrome (PCOS) patients. Biochem Biophys Res Commun. 482:1469–1476. 2017. View Article : Google Scholar : PubMed/NCBI
43	Cai G, Ma X, Chen B, Huang Y, Liu S, Yang H and Zou W: MicroRNA-145 negatively regulates cell proliferation through targeting IRS1 in isolated ovarian granulosa cells from patients with polycystic ovary syndrome. Reprod Sci. 24:902–910. 2017. View Article : Google Scholar : PubMed/NCBI
44	Abruzzese GA, Cerrrone GE, Gamez JM, Graffigna MN, Belli S, Lioy G, Mormandi E, Otero P, Levalle OA and Motta AB: Lipid accumulation product (LAP) and visceral adiposity index (VAI) as markers of insulin resistance and metabolic associated disturbances in young argentine women with polycystic ovary syndrome. Horm Metab Res. 49:23–29. 2017.PubMed/NCBI
45	Temur M, Yılmaz Ö, Aksun S, Calan M, Özbay Özün P, Kumbasar S and Sever E: The relationship of urocortin-2 with insulin resistance patients having PCOS. Gynecol Endocrinol. 33:124–127. 2017. View Article : Google Scholar : PubMed/NCBI
46	Boden G, Homko C, Barrero CA, Stein TP, Chen X, Cheung P, Fecchio C, Koller S and Merali S: Excessive caloric intake acutely causes oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men. Sci Transl Med. 7:304re72015. View Article : Google Scholar : PubMed/NCBI
47	Fazakerley DJ, Naghiloo S, Chaudhuri R, Koumanov F, Burchfield JG, Thomas KC, Krycer JR, Prior MJ, Parker BL, Murrow BA, et al: Proteomic analysis of GLUT4 storage vesicles reveals tumor suppressor candidate 5 (TUSC5) as a novel regulator of insulin action in adipocytes. J Biol Chem. 290:23528–23542. 2015. View Article : Google Scholar : PubMed/NCBI
48	Belman JP, Bian RR, Habtemichael EN, Li DT, Jurczak MJ, Alcázar-Román A, McNally LJ, Shulman GI and Bogan JS: Acetylation of TUG protein promotes the accumulation of GLUT4 glucose transporters in an insulin-responsive intracellular compartment. J Biol Chem. 290:4447–4463. 2015. View Article : Google Scholar : PubMed/NCBI
49	Leto D and Saltiel AR: Regulation of glucose transport by insulin: Traffic control of GLUT4. Nat Rev Mol Cell Biol. 13:383–396. 2012. View Article : Google Scholar : PubMed/NCBI
50	Rowe RG, Wang LD, Coma S, Han A, Mathieu R, Pearson DS, Ross S, Sousa P, Nguyen PT, Rodriguez A, et al: Developmental regulation of myeloerythroid progenitor function by the Lin28b-let-7-Hmga2 axis. J Exp Med. 213:1497–1512. 2016. View Article : Google Scholar : PubMed/NCBI
51	Fedele M, Palmieri D and Fusco A: HMGA2: A pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol. 326:19–24. 2010. View Article : Google Scholar : PubMed/NCBI
52	Han J, Li E, Chen L, Zhang Y, Wei F, Liu J, Deng H and Wang Y: The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1. Nature. 524:243–246. 2015. View Article : Google Scholar : PubMed/NCBI
53	Gorgani-Firuzjaee S and Meshkani R: SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR/SREBP1 pathway and ROS production in HepG2 cells. Free Radic Biol Med. 89:679–689. 2015. View Article : Google Scholar : PubMed/NCBI